Skip to main navigation
  • Careers
  • Contact

Menu

Skip to content
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • SEC Filings
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Estimates
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • ADCs
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • ZTlido™
      • RTX
  • Translational Efficiencies

News Releases

fundamentals sub menu

  • Fundamentals

Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates

Sep 05, 2019

Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants

Jul 02, 2019

Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

Jun 28, 2019

Sorrento Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Jun 28, 2019

Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy

Jun 19, 2019

Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

Jun 19, 2019

Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)

Jun 14, 2019

Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company

Jun 12, 2019

Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain

Jun 10, 2019

Scilex Holding Announces Strong ZTlido Sales Growth After Successful Post-Merger Integration

Jun 05, 2019

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Email Page
Clinical Trials
clinicaltrials@sorrentotherapeutics.com
Investors
investors@sorrentotherapeutics.com
Business Development
business@sorrentotherapeutics.com
Media Requests
mediarelations@sorrentotherapeutics.com
© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • DMCA
  • Trademarks
  • Linking Policy
  • LinkedIn
MENU
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Analyst Coverage
      • Estimates
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • Quarterly Results
      • Fundamentals
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Investor Contact
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • Antibody Drug Conjugates (ADCs)
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • RTX
      • ZTlido™
  • Translational Efficiencies
  • Careers
  • Contact